Poor clinical outcomes in many cancers are associated with the invasion of abundant FOXP3+ cells into the tumour tissue [29]; therefore, higher recurrence risk is also expected in the case of higher FOXP3+ expression in CRC. The gene discussed is FOXP3; the disease is neoplasm.